MA27140A1 - Les oligopeptides et les compositions qui les contiennent en tant qu'inhibiteurs de cathepsin s - Google Patents

Les oligopeptides et les compositions qui les contiennent en tant qu'inhibiteurs de cathepsin s

Info

Publication number
MA27140A1
MA27140A1 MA27611A MA27611A MA27140A1 MA 27140 A1 MA27140 A1 MA 27140A1 MA 27611 A MA27611 A MA 27611A MA 27611 A MA27611 A MA 27611A MA 27140 A1 MA27140 A1 MA 27140A1
Authority
MA
Morocco
Prior art keywords
cathepsin
oligopeptides
inhibitors
compositions containing
compositions
Prior art date
Application number
MA27611A
Other languages
English (en)
Inventor
Jiayao Li
David J Aldous
Original Assignee
Aventis Pharma Inc
Axys Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc, Axys Pharm Inc filed Critical Aventis Pharma Inc
Publication of MA27140A1 publication Critical patent/MA27140A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
MA27611A 2001-11-14 2004-04-06 Les oligopeptides et les compositions qui les contiennent en tant qu'inhibiteurs de cathepsin s MA27140A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33260501P 2001-11-14 2001-11-14

Publications (1)

Publication Number Publication Date
MA27140A1 true MA27140A1 (fr) 2005-01-03

Family

ID=23298977

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27611A MA27140A1 (fr) 2001-11-14 2004-04-06 Les oligopeptides et les compositions qui les contiennent en tant qu'inhibiteurs de cathepsin s

Country Status (21)

Country Link
US (3) US6977256B2 (fr)
EP (1) EP1446392A1 (fr)
JP (1) JP2005514353A (fr)
KR (1) KR20050044497A (fr)
CN (1) CN1324018C (fr)
BR (1) BR0214104A (fr)
CA (1) CA2467391A1 (fr)
CO (1) CO5640128A2 (fr)
HK (1) HK1073840A1 (fr)
HR (1) HRP20040426A2 (fr)
HU (1) HUP0401906A3 (fr)
IL (1) IL161950A0 (fr)
MA (1) MA27140A1 (fr)
MX (1) MXPA04004450A (fr)
NO (1) NO20041909L (fr)
NZ (1) NZ532167A (fr)
PL (1) PL372105A1 (fr)
RU (1) RU2004117877A (fr)
WO (1) WO2003042197A1 (fr)
YU (1) YU34604A (fr)
ZA (1) ZA200403602B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL369312A1 (en) * 2001-09-14 2005-04-18 Aventis Pharmaceuticals Inc. Novel compounds and compositions as cathepsin inhibitors
YU34604A (sh) * 2001-11-14 2006-08-17 Aventis Pharmaceuticals Inc. Oligopeptidi kao inhibitori katepsina s i kompozicije koje ih sadrže
US7091360B2 (en) * 2002-04-16 2006-08-15 Aventis Pharma S.A. Process for preparing heteroaryl and unsaturated heterocycloalkylmagnesium reagents and uses thereof
WO2004028521A2 (fr) 2002-09-24 2004-04-08 Novartis Ag Composes organiques
JP5587790B2 (ja) 2008-01-09 2014-09-10 アミュラ セラピューティクス リミティド 化合物
KR20160131126A (ko) 2008-06-20 2016-11-15 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물
US8895497B2 (en) * 2009-12-04 2014-11-25 Dcb-Usa, Llc Cathepsin S inhibitors

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874424A (en) 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
DE3606480A1 (de) * 1986-02-28 1987-09-03 Behringwerke Ag Oligopeptidylnitrilderivate, diese enthaltende mittel, verfahren zu ihrer herstellung und ihre verwendung
US5055451A (en) 1986-12-22 1991-10-08 Syntex Inc. Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
GB8809316D0 (en) 1987-05-11 1988-05-25 Ici America Inc Heterocyclic ketones
JPS63303868A (ja) 1987-06-03 1988-12-12 Oki Electric Ind Co Ltd 誘電体セラミックスの製造方法
DE3827415A1 (de) 1988-08-12 1990-02-15 Behringwerke Ag Peptidderivate, verfahren zu ihrer herstellung und ihre verwendung
EP0376012A3 (fr) 1988-12-27 1992-05-06 American Cyanamid Company Inhibiteurs de la rénine
WO1990012005A1 (fr) 1989-04-13 1990-10-18 Japan Tobacco Inc. Nouveaux derives aminoacides possedant une activite d'inhibiteur de la prolylendopeptidase
AU643300B2 (en) 1990-06-07 1993-11-11 Zeria Pharmaceutical Co., Ltd. Novel arylalkanoylamine derivative and drug containing the same
JPH06192199A (ja) 1992-12-25 1994-07-12 Mitsubishi Kasei Corp ケトン誘導体
CA2111930A1 (fr) * 1992-12-25 1994-06-26 Ryoichi Ando Derives d'aminocetones
IL110525A0 (en) 1993-08-09 1994-11-11 Lilly Co Eli Identification and use of protease inhibitors
BR9408019A (pt) 1993-11-09 1997-08-26 Merck & Co Inc Composto composição util para aumentar a produção endógena ou a liberaçao de hormonio do crescimento em ser humano ou um animal e para o tratamento da osteoporose processos para aumentar os niveis de hormônio do crescimento em um ser humano ou um animal e a eficácia de alimentação promover o crescimento aumentar a produçao de leite e melhorar a qualidade da carcaça de gado para tratar ou previnir uma condição selecionada para tratar osteoporose e para preparar um composto
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5486623A (en) * 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
US5714484A (en) 1993-12-08 1998-02-03 Prototek, Inc. α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors
JPH07228529A (ja) 1994-02-17 1995-08-29 Zeria Pharmaceut Co Ltd コリンエステラーゼ賦活剤
US6143790A (en) 1994-03-10 2000-11-07 G.D. Searle & Co. L-N6 -(1-iminoethyl)lysine derivatives useful as nitric oxide synthase inhibitors
US5847135A (en) * 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5498616A (en) * 1994-11-04 1996-03-12 Cephalon, Inc. Cysteine protease and serine protease inhibitors
US6015791A (en) 1994-11-21 2000-01-18 Cortech Inc. Serine protease inhibitors-cycloheptane derivatives
US5691368A (en) 1995-01-11 1997-11-25 Hoechst Marion Roussel, Inc. Substituted oxazolidine calpain and/or cathepsin B inhibitors
CN1071751C (zh) 1995-03-24 2001-09-26 阿克西斯制药公司 可逆蛋白酶抑制剂
US6022861A (en) * 1995-06-07 2000-02-08 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
TW438591B (en) * 1995-06-07 2001-06-07 Arris Pharm Corp Reversible cysteine protease inhibitors
US6069130A (en) 1995-06-07 2000-05-30 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
EP0840614A1 (fr) 1995-06-13 1998-05-13 Sanofi Winthrop, Inc. Inhibiteurs de la calpaine destines au traitement de maladies neurodegeneratives
US6124333A (en) * 1995-06-22 2000-09-26 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
AU6458396A (en) 1995-07-17 1997-02-18 Cephalon, Inc. Phosphorous-containing cysteine and serine protease inhibitors
WO1997021690A1 (fr) * 1995-11-28 1997-06-19 Cephalon, Inc. Inhibiteurs de cysteine et serine proteases derives d'acide d-amine
WO1998001133A1 (fr) 1996-07-08 1998-01-15 Yamanouchi Pharmaceutical Co., Ltd. Inhibiteurs de la resorption osseuse
NZ333696A (en) 1996-07-08 2000-06-23 Du Pont Pharm Co Amidinoindoles, amidinoazoles, and analogs thereof as inhibitors of trypsin like protease enzymes like thrombin and Xa factor
DZ2285A1 (fr) 1996-08-08 2002-12-25 Smithkline Beecham Corp Inhibiteurs de protéase de la cystéine.
EP0923535A4 (fr) 1996-08-28 2001-01-10 Smithkline Beecham Corp Inhibiteurs de cysteine protease
BR9712081B1 (pt) 1996-08-28 2010-12-14 derivado peptÍdico, composto, composiÇço farmacÊutica e composiÇço para ativar o sistema nervoso central.
UA56197C2 (uk) 1996-11-08 2003-05-15 Зенека Лімітед Гетероциклічні похідні
GB9624817D0 (en) 1996-11-28 1997-01-15 British Biotech Pharm Metalloproteinase inhibitors
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
TR200001189T2 (tr) 1997-11-05 2000-09-21 Novartis Ag. Dipeptid nitriller.
GB9723407D0 (en) * 1997-11-05 1998-01-07 Ciba Geigy Ag Organic compounds
US6114310A (en) * 1998-01-23 2000-09-05 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
AU4415899A (en) * 1998-06-03 1999-12-20 Cortech, Inc. Alpha-keto oxadiazoles as serine protease inhibitors
US5998390A (en) * 1998-09-28 1999-12-07 The Research Foundation Of State University Of New York Combination of bisphosphonate and tetracycline
AU2560300A (en) 1999-02-20 2000-09-04 Astrazeneca Ab Acetamido acetonitrile derivatives as inhibitors of cathepsin l and/or cathepsins
AU2560000A (en) 1999-02-20 2000-09-04 Astrazeneca Ab Di- and tripeptide nitrile derivatives as inhibitors of cathepsin l and cathepsin
GB9903861D0 (en) 1999-02-20 1999-04-14 Zeneca Ltd Chemical compounds
JP2002538151A (ja) 1999-03-02 2002-11-12 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド カテプシンの可逆的インヒビターとして有用な化合物
TW200404789A (en) * 1999-03-15 2004-04-01 Axys Pharm Inc Novel compounds and compositions as protease inhibitors
US6506733B1 (en) * 1999-03-15 2003-01-14 Axys Pharmaceuticals, Inc. Compounds and compositions as protease inhibitors
BR0009042A (pt) * 1999-03-15 2001-12-26 Axys Pharm Inc Composto, uso do mesmo, processo para prepararum composto, composição farmacêutica, e, métodospara tratar uma doença em um animal em que aatividade de cisteìna protease contribui para apatologia e/ou sintomatologia da doença, e paratratar uma doença em um animal em que a atividadede catepsina s contribui para a patologia e/ousintomatologia da doença
GB9907683D0 (en) 1999-04-06 1999-05-26 Synphar Lab Inc Substituted azetidin-2-ones as cysteine protease inhibitors
GB9911417D0 (en) 1999-05-18 1999-07-14 Peptide Therapeutics Ltd Furanone derivatives as inhibitors of cathepsin s
JP2001011037A (ja) 1999-07-01 2001-01-16 Kissei Pharmaceut Co Ltd シクロアルカンカルボン酸アミド誘導体
EP1204652B1 (fr) 1999-07-30 2006-05-17 Boehringer Ingelheim Pharmaceuticals Inc. Nouveaux composes de derives de succinate utilises comme inhibiteurs des cysteine proteases
GB9917909D0 (en) 1999-07-31 1999-09-29 Synphar Lab Inc Cysteine protease inhibitors
JP2001055366A (ja) 1999-08-12 2001-02-27 Kissei Pharmaceut Co Ltd ビアリール酢酸アミド誘導体
DK1218372T3 (da) 1999-09-13 2003-10-20 Boehringer Ingelheim Pharma Nye heterocykliske forbindelser, der er anvendelige som reversible inhibitorer af cysteinproteaser
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
MXPA02002873A (es) 1999-09-16 2002-08-30 Axys Pharm Inc Compuestos y composiciones farmaceuticas como inhibidores de la catepsina s.
GB9925264D0 (en) 1999-10-26 1999-12-29 Zeneca Ltd Chemical compounds
HU227039B1 (en) 2000-01-25 2010-05-28 Egis Gyogyszergyar Nyilvanosan New process for the production of quetiapine and intermediates therefor
GB0003111D0 (en) 2000-02-10 2000-03-29 Novartis Ag Organic compounds
US7132449B2 (en) 2001-01-17 2006-11-07 Amura Therapeutics Limited Inhibitors of cruzipain and other cysteine proteases
PT1362052E (pt) 2001-01-17 2007-04-30 Amura Therapeutics Ltd Inibidores de cruzipaína e de outras proteases de cisteína
IL156775A0 (en) 2001-01-17 2004-02-08 Amura Therapeutics Ltd Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases
WO2002096892A1 (fr) 2001-05-31 2002-12-05 Ono Pharmaceutical Co., Ltd. Composes derives d'oxadiazole et medicaments contenant ces composes comme ingredient actif
KR20040015725A (ko) * 2001-06-01 2004-02-19 액시스 파마슈티컬스 인코포레이티드 카텝신 ｓ 억제제로서의 화합물 및 약제학적 조성물
US6982263B2 (en) 2001-06-08 2006-01-03 Boehringer Ingelheim Pharmaceuticals, Inc. Nitriles useful as reversible inhibitors of cysteine proteases
PL369312A1 (en) * 2001-09-14 2005-04-18 Aventis Pharmaceuticals Inc. Novel compounds and compositions as cathepsin inhibitors
YU34604A (sh) * 2001-11-14 2006-08-17 Aventis Pharmaceuticals Inc. Oligopeptidi kao inhibitori katepsina s i kompozicije koje ih sadrže

Also Published As

Publication number Publication date
CN1324018C (zh) 2007-07-04
KR20050044497A (ko) 2005-05-12
CN1585757A (zh) 2005-02-23
US20030199506A1 (en) 2003-10-23
IL161950A0 (en) 2005-11-20
CA2467391A1 (fr) 2003-05-22
HUP0401906A3 (en) 2008-07-28
PL372105A1 (en) 2005-07-11
NO20041909L (no) 2004-05-10
YU34604A (sh) 2006-08-17
JP2005514353A (ja) 2005-05-19
HK1073840A1 (en) 2005-10-21
EP1446392A1 (fr) 2004-08-18
MXPA04004450A (es) 2004-08-11
US7226921B2 (en) 2007-06-05
BR0214104A (pt) 2004-09-28
HUP0401906A2 (hu) 2004-12-28
US6977256B2 (en) 2005-12-20
CO5640128A2 (es) 2006-05-31
US20050267044A1 (en) 2005-12-01
WO2003042197A1 (fr) 2003-05-22
US20070203138A1 (en) 2007-08-30
NZ532167A (en) 2006-11-30
HRP20040426A2 (en) 2004-10-31
ZA200403602B (en) 2005-08-31
RU2004117877A (ru) 2006-01-10

Similar Documents

Publication Publication Date Title
FR15C0086I2 (fr) Derives d'hydroxamate en tant qu'inhibiteurs de desacetylase
MA27126A1 (fr) 3'PROMEDICAMENTS DE 2'-DESOXY- β-L-NUCLEOSIDES
MA26994A1 (fr) Quinazolines en tant qu'inhibiteurs de la mmp-13
NO2012018I1 (no) Canakinumab eller direkte ekvivalenter derav
DK1395242T3 (da) Flydende farmaceutisk sammensætning
DE50201627D1 (de) Gefrierschutzmittelkonzentrate enthaltend den farbstoff c.i. reactive violet 5
EE05020B1 (et) Glburiidi ravimkoostis
DK1425005T3 (da) Farmaceutisk sammensætning indeholdende lumiracoxib
HK1073840A1 (en) Oligopeptides and compositions containing them as cathepsin s inhibitors
IL156711A0 (en) Peptide derivatives and pharmaceutical compositions containing the same
ATE308242T1 (de) Phytopharmazeutische zusammensetzungen in form von legierungen
MA25509A1 (fr) Composition destinee au traitement de l'hepatite c
ITMI20011833A0 (it) Agenti che regolano la permeabilita' vascolare
ITMI20020158A0 (it) Procedimento atto all'individuazione di incendi
NO20042803L (no) 1,3-diarylprop-2en-1-oner, preparater inneholdende forbindelsene samt anvendelse derav
ITPI20010055A0 (it) Dispositivo per l'applicazione di protesi vascolari e protesi vascolare cosi' utilizzata
UA3771S (uk) Етикетка лікарського препарату "цитрамон-екстра"
UA5696S (uk) Костюм чоловічий
ITRM20010213A0 (it) Valvola di sicurezza antiprofondita'.
FR2807033B1 (fr) Compositions de mono- et poly- benzyl-1,2,3,4- tetrahydronaphtalenes
UA5969S (uk) Чоботи чоловічі
UA5967S (uk) Напівчеревики чоловічі
UA5424S (uk) Етикетка "sarzhyn yar"
ITBA20010026V0 (it) Montart: l'espositore universale
FI5135U1 (fi) Miesten housunsuoja